BioMarin Closes $850M Senior Unsecured Notes Offering to Fund Amicus Acquisition
BMRN sits 18% above its 52-week low of $50.76.
Summary
BioMarin Pharmaceutical Inc. announced the closing of its $850 million private offering of 5.500% senior unsecured notes due 2034, a key financing step for its pending acquisition of Amicus Therapeutics, Inc.
Key Events · Financing and Capital Events · BMRN
-
Closing of $850M Notes Offering
BioMarin Pharmaceutical Inc. closed its previously announced private offering of $850 million aggregate principal amount of 5.500% Senior Notes due 2034.
-
Funding for Amicus Acquisition
The net proceeds from the notes offering, along with other debt facilities, will fund the pending acquisition of Amicus Therapeutics, Inc. and related expenses.
-
Escrow and Special Redemption Terms
Gross proceeds are held in an escrow account, with a special mandatory redemption required if the Amicus acquisition is not completed by December 19, 2026.
Analysis · BMRN · Life Sciences
BioMarin Pharmaceutical Inc. announced the closing of its $850 million private offering of 5.500% senior unsecured notes due 2034. This transaction finalizes a significant portion of the debt financing package initiated on January 26, 2026, and priced on January 29, 2026, which is intended to fund the pending acquisition of Amicus Therapeutics, Inc. The gross proceeds from the notes offering have been deposited into an escrow account, with a special mandatory redemption provision if the acquisition is not completed by December 19, 2026. This closing confirms the successful execution of a substantial capital raise, providing necessary funding for the company's strategic M&A activity.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRN was trading at $59.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $50.76 to $73.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.